| abstract |
Isolated peptides and combinations of peptides derived from myelin autoantigens such as MBP, MOG, PLP and MAG are suitable for the treatment of multiple sclerosis, including prophylactic and therapeutic compositions and methods for the prevention or treatment of multiple sclerosis. Preferred compositions disclosed include at least one isolated, purified peptide free from all other peptides or contaminants, the peptide comprising an amino acid sequence, the myelin autoantigen having T cell activity. A therapeutic composition described is capable of down-regulating the autoantigen with specific immune response to the myelin autoantigen in a population of people suffering from or susceptible to multiple sclerosis so that the disease symptoms are reduced, eliminated or reversed and / or the onset or progression of the disease symptoms prevented or decreased. In addition, the compositions and methods described, when administered at an advanced stage of the disease, may reverse ongoing paralysis or other signs of the disease when administered during the acute phase of the disease or prevent relapse when administered during remission. |